SCHEMBL5680406

SCHEMBL5680406

Cc1ccccc1C(=O)OC[C@H]1O[C@@H](OC(=O)c2ccccc2C)[C@](C)(OC(=O)c2ccccc2C)[C@@H]1OC(=O)c1ccccc1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.37
ADRB1 P08588 2/20 0.37
ADRB3 P13945 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
TDP1 Q9NUW8 2/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 2/20 0.35
BCHE P06276 1/20 0.35
MAPT P10636 4/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5682285 0.93 ALDH1A1 (0.41) ADRB2ADRB1ADRB3L3MBTL1KMT2A
SCHEMBL5680332 0.90 TSHR (0.38) ADRB2ADRB1ADRB3L3MBTL1KMT2A
SCHEMBL1824333 0.87 TSHR (0.39) ADRB2ADRB1ADRB3L3MBTL1KMT2A
SCHEMBL19276651 0.81 ALDH1A1 (0.49) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL21418908 0.81 ALDH1A1 (0.49) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL14853799 0.81 ALDH1A1 (0.49) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL721635 0.81 ALDH1A1 (0.49) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL21418911 0.81 ALDH1A1 (0.49) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL14571165 0.81 ALDH1A1 (0.49) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL882168 0.81 ALDH1A1 (0.49) KMT2AMEN1TDP1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631573-A1 PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES INALCO SpA (IT) 2006-03-08 EP disclosed
US-6891036-B2 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2005-05-10 US disclosed
WO-2004069851-A1 PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES INALCO S.P.A. (IT) 2004-08-19 WO disclosed
US-20040158059-A1 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158059-A1 Process for the preparation of ribofuranose derivatives RNGTT, RPIA, MRM1 ADRB2 4776/4885ADRB1 4238/4885ADRB3 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.